Skip to main content
. 2014 Oct 24;7(5):590–604. doi: 10.1016/j.tranon.2014.08.001

Figure 11.

Figure 11

Combinatory effects of NVP-AUY922 with other drugs. (A) CFPAC-1 and (B) PANC-1 pancreatic cancer cells were treated with different concentrations of gemcitabine (0.01, 0.1, 0.5, and 1 μM) in the absence or presence of 0.01 μM NVP-AUY922 for 72 hours and cell proliferation was determined. Curves for gemcitabine alone, experimental curves for gemcitabine and NVP-AUY922, and theoretical (Ebliss) curves for gemcitabine and NVP-AUY922 are represented. (C) HCT-15 colorectal carcinoma cells were treated with various concentrations of oxaliplatin (0.1, 0.5, 1, and 5 μM) in the absence or presence of 0.01 μM NVP-AUY922. Curve for oxaliplatin alone, experimental curves for oxaliplatin and NVP-AUY922, and theoretical (Ebliss) curves for oxaliplatin and NVP-AUY922 are represented. (D) DLD-1 colorectal carcinoma cells were treated with varying concentrations of AZD6244 (0.01, 0.1, 0.5, and 1 μM) in the absence or presence of 0.005 μM NVP-AUY922. Curve for AZD6244 alone, experimental curves for AZD6244 and NVP-AUY922, and theoretical (Ebliss) curves for AZD6244 and NVP-AUY922 are represented. (E) PANC-1 pancreatic carcinoma cells were treated with different concentrations of NVP-BEZ235 (BEZ235; 0.001, 0.01, 0.05, and 0.1 μM) in the absence or presence of 0.01 μM NVP-AUY922. Curve for BEZ235 alone, experimental curves for BEZ235 and NVP-AUY922, and theoretical (Ebliss) curves for BEZ235 and NVP-AUY922 are represented. In all graphs, results represent the average of three independent experiments and error bars are the SEM. Each experiment was performed in sextuplicate (n = 6).